Pharmalot By Ed Silverman Pharmalittle: Endo pays $50 million to settle opioid case; Senate mulls pegging drug prices to VA discounts
Biotech By Adam Feuerstein The future of Apellis Pharma’s eye disease treatment is clouded by divergent study results
Exclusive By Nicholas Florko and Rachel Cohrs Senate considers pegging Medicare drug prices to deeply discounted Veterans Affairs rates
Pharmalot By Ed Silverman Pharmalittle: Biden drug-pricing plan backs Medicare negotiations; Moderna tests combined Covid-19 booster and flu shot
Biotech By Matthew Herper FDA’s rejection of Humanigen drug highlights problems in developing Covid-19 treatments
Opinions+ By Dawn Anderson Digital clinical trials can personalize patient engagement, accelerate therapy development
Pharmalot By Kate Sheridan Pharmalittle: Sanofi will acquire Kadmon Pharma for $1.9 billion; Theranos founder Elizabeth Holmes goes on trial
Biotech By Kate Sheridan In another sign of RNA’s growing popularity, the cancer startup Replicate is relaunching
Health Tech By Erin Brodwin and Casey Ross Inside Verily’s make-or-break push to turn its most promising ideas into profits
Biotech By Kate Sheridan FDA dings Kaleido Biosciences for testing a microbiome drug without proper paperwork
Biotech By Matthew Herper and Kate Sheridan STAT+ Conversation: Which biotech venture capital funds performed best during the pandemic?
Pharmalot By Nicholas St. Fleur Pharmalittle: CEPI warns of hurdle to new Covid-19 vaccines; reading tea leaves on booster side effects
Politics By Nicholas Florko The FDA has just 3 days to decide how to regulate 6.5 million e-cigarette products. But what if it blows past the deadline?
Politics By Rachel Cohrs Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?
Pharmalot By Ed Silverman Pharmalittle: Lawmakers ramp up probe of FDA approval of Biogen drug; EU to return J&J Covid-19 shots to Africa
Opinions+ By Monique K. Mansoura A 10-point plan for sustaining the biopharma industrial base for a more secure nation
Exclusive By Erin Brodwin Cityblock Health raises another mega-round of funding, tipping its valuation over $5 billion
Pharmalot By Ed Silverman Older job seekers claim that Lilly favors millennials when it comes to hiring sales reps
Biotech By Jon Chesto — Boston Globe Boston Scientific completes $1 billion acquisition of Israeli firm
Pharmalot By Ed Silverman Pharmalittle: Purdue bankruptcy plan is approved but appeals expected; FDA warns about safety risks with arthritis drugs
Pharmalot By Ed Silverman Pharmalittle: Two key FDA officials leaving amid Covid-19 booster debate; is Biden really ‘following the science’?
Politics By Nicholas Florko and Lev Facher Two top FDA officials in charge of Covid-19 vaccines to leave agency this fall
Pharmalot By Ed Silverman Pharmalittle: BIO wrestles with inner turmoil; J&J HIV vaccine failed to prevent infection
Exclusive By Nicholas Florko ‘Change is messy’: Inside the tumultuous efforts to stabilize BIO, the biotech lobby
Pharmalot By Ed Silverman ‘A step in the right direction for national security’: An antibiotic plant reopens in Tennessee to make penicillin
